Robert Snoeck
About
In The Last Decade
Robert Snoeck
546 papers receiving 16.8k citations
Hit Papers
Peers
Comparison fields: 5 of 157
- Epidemiology 6.5k
- Organic Chemistry 5.5k
- Molecular Biology 5.0k
- Infectious Diseases 4.8k
- Virology 3.0k
Countries citing papers authored by Robert Snoeck
This map shows the geographic impact of Robert Snoeck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Snoeck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Snoeck more than expected).
Fields of papers citing papers by Robert Snoeck
This network shows the impact of papers produced by Robert Snoeck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Snoeck. The network helps show where Robert Snoeck may publish in the future.
Co-authorship network of co-authors of Robert Snoeck
This figure shows the co-authorship network connecting the top 25 collaborators of Robert Snoeck. A scholar is included among the top collaborators of Robert Snoeck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Snoeck. Robert Snoeck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 5 | |
| 3 | 1 | |
| 4 | 15 | |
| 5 | 7 | |
| 6 | 32 | |
| 7 | 323 | |
| 8 | 4 | |
| 9 | 18 | |
| 10 | 11 | |
| 11 | Tecovirimat, a p37 envelope protein inhibitor for the treatment of smallpox infection. | 29 |
| 12 | New therapeutic weapons against poxvirus | 1 |
| 13 | 70 | |
| 14 | Reduced pathogenicity of phenotypically and genotypically characterized cidofovir (CDV)-resistant vaccinia virus (VV) | 1 |
| 15 | Synthesis and biological evaluation of bicyclic furano pyrimidine nucleosides as inhibitors of human cytomegalovirus | 2 |
| 16 | New bicyclic nucleoside analogues (BCNAs) show selective and specific activity against human cytomegalovirus (HCMV) | 1 |
| 17 | Anti-varicella-zoster virus bicyclic nucleosides: Synthesis and in vitro evaluation of 2 ',3 '-dideoxy nucleoside derivatives | 1 |
| 18 | Susceptibilities of several drug-resistant varicella-zoster virus (VZV) strains to bicyclic pyrimidine nucleoside analogues (BCNAs) | 3 |
| 19 | 6 | |
| 20 | Treatment of herpes simplex virus infections | 3 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.